Business Context and Reporting Period
Company: SANUWAVE Health, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 13, 2019
Event: Entry into a Material Definitive Agreement (Joint Venture).
On December 13, 2019, SANUWAVE Health, Inc. entered into a joint venture agreement with Universus Global Advisors LLC, Versani Health Consulting, Curacus Limited, and certain individuals (collectively the "IDIC Group"). The joint venture aims to manufacture, import, sell, and distribute dermaPACE devices and wound kits exclusively in Brazil using extracorporeal shockwave therapy technology.
Key Financial Metrics and Transaction Terms
This filing details a specific transaction rather than general financial performance. Key financial terms include:
- Total Partnership Fee: $600,000 paid by the IDIC Group to the Company for exclusive territorial rights in Brazil.
- Payment Schedule:
- $250,000 paid on November 14, 2019 (initially a loan, forgiven on December 13, 2019).
- $250,000 paid on December 31, 2019.
- $100,000 payable upon receipt of regulatory approvals from ANVISA (Brazilian Health Regulatory Agency).
- Equity Structure:
- Company: 45%
- IDIC Group: 45%
- Versani: 5%
- Universus: 5%
- Supply Terms: The Company will supply devices at cost. The initial five devices are provided on deferred payment terms, due when the joint venture reaches $1,000,000 in gross sales.
Material Changes and Agreements
The primary material change is the establishment of the Brazil joint venture. The filing does not provide comparative financial data (revenue, profit, cash flow) for the reporting period versus prior periods. The agreement includes specific conditions precedent that must be met by December 31, 2020, or the agreement may be terminated.
Outlook, Risks, and Contingencies
Regulatory Risk: The final $100,000 payment and the operation of the joint venture are contingent upon approval from ANVISA. If ANVISA denies approval or grants it with material restrictions, the IDIC Group may terminate the agreement and demand a refund of the partnership fee plus organizational expenses.
Change of Control Provisions:
- Pre-$2M Sales: If a change of control occurs before the joint venture achieves $2,000,000 in gross sales, the Company's new controlling entity must buy out other parties at 4x their total investment.
- Post-$2M Sales: If a change of control occurs after $2,000,000 in gross sales, the buyout price is 12x the net sales of the previous 12 months. Additionally, other parties have a put right to sell their interests based on the EBITDA multiple paid for the Company's acquisition.
Management: The joint venture will be managed by a four-member board (two appointed by the Company, two by the IDIC Group). The IDIC Group appoints the Chairman.
Investor Verification Checklist
- Verify the receipt of the $250,000 payment made on December 31, 2019.
- Monitor the status of ANVISA regulatory approvals, which trigger the final $100,000 payment and operational launch.
- Review the upcoming agreements (shareholders', trademark license, supply, and technology license) scheduled for execution by January 31, 2020.
- Assess the impact of the change of control clauses on potential future M&A activity involving SANUWAVE Health, Inc.
- Confirm the timeline for the joint venture to reach $1,000,000 in gross sales to trigger payment for the initial five devices.